Skip to main content
Log in

Trimegestone

RU 27987

  • Adis R&D Profile
  • Section 1: Osteoporosis
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ross D, Godfree V, Cooper A, et al. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas 1997 Sep; 28: 83–8

    Article  PubMed  CAS  Google Scholar 

  2. Wahab M, Thompson J, Bell S, et al. Effect of trimegestonebased HRT on the bleeding pattern and on endometrial expression of Mib-1 and bcl-2 in postmenopausal women: a dose-ranging study. Br J Obstet Gynaecol 1998 Jul; 105 Suppl. 17: 13

    Google Scholar 

  3. Wahab M, Thompson J, Al-Azzawi F. Factors influencing the pattern of uterine bleeding in postmenopausal women. Br J Obstet Gynaecol 1998 Jul; 105 Suppl. 17: 102

    Google Scholar 

  4. Ross D, Marsh MS, Godfrey V, et al. Endometrial effects of three doses of sequential oral trimegestone with continuous oral 17-beta estradiol in postmenopausal women. Fertil Steril 1995; Program Suppl.: 91–2

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trimegestone. Drugs R&D 1, 228–229 (1999). https://doi.org/10.2165/00126839-199901030-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901030-00010

Keywords

Navigation